Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Select Relapsed/Refractory Lymphoid Malignancies”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT02790515
What this trial is testing

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myeloid Sarcoma+4 more
St. Jude Children's Research Hospital 170
Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Early research (Phase 1)Study completedNCT00278330
What this trial is testing

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Who this might be right for
Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid Leukemia+4 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Early research (Phase 1)Study completedNCT00710528
What this trial is testing

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)+1 more
Gilead Sciences 192
Early research (Phase 1)Study completedNCT01871675
What this trial is testing

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Who this might be right for
LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+1 more
SCRI Development Innovations, LLC 48
Large-scale testing (Phase 3)Looking for participantsNCT07139873
What this trial is testing

DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Who this might be right for
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals 250
Early research (Phase 1)Study completedNCT00217412
What this trial is testing

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Who this might be right for
Childhood Acute Promyelocytic Leukemia (M3)Childhood Atypical Teratoid/Rhabdoid TumorChildhood Burkitt Lymphoma+16 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Testing effectiveness (Phase 2)Ended earlyNCT01620216
What this trial is testing

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRecurrent Acute Lymphoblastic Leukemia+3 more
OHSU Knight Cancer Institute 12
Large-scale testing (Phase 3)WithdrawnNCT06205290
What this trial is testing

Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-Cell
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT02952508
What this trial is testing

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Who this might be right for
Waldenstrom MacroglobulinemiaMultiple MyelomaChronic Lymphocytic Leukemia+6 more
Cellectar Biosciences, Inc. 120
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Testing effectiveness (Phase 2)UnknownNCT01037556
What this trial is testing

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphocytic Leukemia
Proacta, Incorporated 50
Early research (Phase 1)Looking for participantsNCT06708897
What this trial is testing

Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Who this might be right for
CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)+2 more
Lomond Therapeutics Holdings, Inc. 84
Early research (Phase 1)Ended earlyNCT06761586
What this trial is testing

AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

Who this might be right for
Select Relapsed/Refractory Lymphoid Malignancies
Aurigene Discovery Technologies Limited 9
Testing effectiveness (Phase 2)Looking for participantsNCT05702853
What this trial is testing

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Who this might be right for
B-cell Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Medical University of South Carolina 27
Testing effectiveness (Phase 2)Looking for participantsNCT03938987
What this trial is testing

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL
University of Alberta 63
Large-scale testing (Phase 3)Active Not RecruitingNCT06970743
What this trial is testing

BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines 153
Next Page